Artelo Biosciences to Present at the 13th Congress of the European Pain Federation on September 20th
September 13, 2023 08:30 ET
|
Artelo Biosciences
SOLANA BEACH, Calif., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
Artelo Biosciences Completes Positive Pre-IND Meeting with FDA for ART26.12
September 07, 2023 08:00 ET
|
Artelo Biosciences
SOLANA BEACH, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
Artelo Biosciences to Present at the 6th Cannabinoid-Derived Drug Development Summit on September 12th
September 06, 2023 09:00 ET
|
Artelo Biosciences
SOLANA BEACH, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
Artelo Biosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference on September 13th
September 05, 2023 09:00 ET
|
Artelo Biosciences
SOLANA BEACH, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
Artelo Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update
August 10, 2023 08:00 ET
|
Artelo Biosciences
SOLANA BEACH, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
Artelo Biosciences to Present New Mechanism of Action Data on ART26.12 at the Gordon Research Conference on July 20, 2023
July 19, 2023 09:00 ET
|
Artelo Biosciences
SOLANA BEACH, Calif., July 19, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
Artelo Biosciences CEO to Participate in the Benzinga All Access Event on July 11
July 10, 2023 08:30 ET
|
Artelo Biosciences
SOLANA BEACH, Calif., July 10, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
Artelo Biosciences Announces Sponsorship of The William A. Devane Early Career Investigator Award at the 33rd Annual International Cannabinoid Research Society Symposium
June 28, 2023 08:30 ET
|
Artelo Biosciences
SOLANA BEACH, Calif., June 28, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
Artelo Biosciences Announces Important New Data on ART26.12 Demonstrating Positive Effects in Multiple Models of Neuropathic Pain at the 33rd Annual International Cannabinoid Research Society Symposium
June 27, 2023 08:30 ET
|
Artelo Biosciences
ART26.12, a Novel Fatty Acid Binding Protein 5 (FABP5) Inhibitor, Shows Favorable Results in Studies for Chemotherapy-Induced Neuropathy and Diabetic Neuropathy ART26.12 targeting global neuropathic...
Artelo Biosciences Reports Superior Preclinical Pharmaceutical Properties and Efficacy of ART12.11 Compared to Cannabidiol (CBD) at the 33rd Annual International Cannabinoid Research Society Symposium
June 26, 2023 08:30 ET
|
Artelo Biosciences
ART12.11, a novel and patented cocrystal of CBD reverses the impact of chronic stress on outcomes of anxiety, depression, sociability and cognition ART12.11 aims to address unmet needs within the...